Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

Barry Wilson

Non-Executive Director

Barry W Wilson, Non-Executive Director, joined the NetScientific Board in 2013. Barry is an international executive with 40+ years of experience in both the pharmaceutical and medical device industries.

He has served as the President of Medtronic International, President of Lederle International prior to its merger with Wyeth, and President of Bristol-Myers Squibb Europe. Additionally he had 9 international assignments with Pfizer. Barry serves on the Board of Welch Allyn and Anecova. He is a member of the Thematic Advisory Board of Lombard Odier Private Bank.

Barry advises several Venture Capital organisations/start-ups. He worked with DLJ Credit-Suisse Alternative Investments as their Healthcare Advisor and served on the boards of Mallinckrodt Inc, Bausch + Lomb (both NYSE) and Rezidor Hotel Group AB (Swedish stock exchange).

Barry Wilson - NetScientific
No announcement available or all announcement expired.